An earlier study using DC vaccines as maintenance therapy in AML patients in CR with MRD after chemotherapy, which included PRAME and Wilm’s Tumor 1 (WT1) as target antigens, demonstrated an overall survival at five years of 75%, with 70% of patients ≥ 60 years of age being long-term survivors. Here, WT1 is linked to acute myeloid leukemia.